Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.71 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL4533958 | 0.94 | SIGMAR1 (0.65) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| SCHEMBL957621 | 0.83 | SIGMAR1 (1.00) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| SCHEMBL955900 | 0.80 | SIGMAR1 (0.77) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| SCHEMBL954292 | 0.79 | SIGMAR1 (0.77) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| Oxalic Acid SCHEMBL466885 | 0.79 | SIGMAR1 (0.90) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| SCHEMBL4098226 | 0.79 | SIGMAR1 (0.60) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| SCHEMBL14721815 | 0.79 | SIGMAR1 (0.60) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| SCHEMBL16352698 | 0.77 | SIGMAR1 (0.44) | SIGMAR1TMEM97 | |
| Oxalic Acid SCHEMBL957600 | 0.76 | SIGMAR1 (0.70) | SIGMAR1SLC18A3DRD2CARM1PRMT6 | |
| SCHEMBL958103 | 0.75 | SIGMAR1 (0.70) | SIGMAR1SLC18A3DRD2TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996548-B1 | SIGMA RECEPTOR COMPOUNDS | ESTEVE LABOR DR (ES) | 2016-01-06 | — | — | EP | claimed |
| US-8481567-B2 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-07-09 | — | — | US | claimed |
| US-20090197915-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-06 | — | — | US | claimed |
| EP-1829862-A1 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| EP-1996548-B1 | SIGMA RECEPTOR COMPOUNDS | ESTEVE LABOR DR (ES) | 2016-01-06 | — | — | EP | disclosed |
| EP-1996548-B1 | SIGMA RECEPTOR COMPOUNDS | ESTEVE LABOR DR (ES) | 2016-01-06 | — | — | EP | disclosed |
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-8481567-B2 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-07-09 | — | — | US | disclosed |
| US-8481567-B2 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-07-09 | — | — | US | disclosed |
| US-20090197915-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| US-20090197915-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| US-20090197915-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| EP-1996548-A1 | SIGMA RECEPTOR COMPOUNDS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007098962-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007098962-A1 | SIGMA RECEPTOR COMPOUNDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
| EP-1829862-A1 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | disclosed |
| EP-1829862-A1 | Sigma receptor compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | SIGMAR1 3/4885SLC18A3 9/4885DRD2 164/4885 |
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | SIGMAR1 3/4885SLC18A3 9/4885DRD2 164/4885 |
| US-20090197915-A1 | SIGMA RECEPTOR COMPOUNDS | SIGMAR1, OPRL1, OPRK1 | SIGMAR1 1/4885SLC18A3 330/4885DRD2 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.